Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease
The approval was based on data from the phase 3 FIDELIO-DKD trial.
The approval was based on data from the phase 3 FIDELIO-DKD trial.
Soaanz is a loop diuretic with an extended duration of action lasting approximately 6 to 8 hours.
The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
Investigators recommended close surveillance after COVID-19 vaccination of kidney transplant recipients and suggested the possibility that a third dose may be required in less responsive patients.
Terlipressin is more effective for reversal of HRS but is associated with more adverse events and death due to respiratory disorders
Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation.
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.